Qin Shanlu,Dong Kuiran.Research advances in embryological origin of Wilms tumor[J].Journal of Clinical Pediatric Surgery,2024,(07):697-700.[doi:10.3760/cma.j.cn101785-202207041-018]
肾母细胞瘤胚胎学起源的研究进展
- Title:
- Research advances in embryological origin of Wilms tumor
- Keywords:
- Wilms Tumor; Non-coding RNA; Methylation; Surgical Procedures; Operative; Child
- 摘要:
- 肾母细胞瘤(Wilms tumor,WT)是最常见的儿童肾脏恶性肿瘤,以伴有多种先天性异常综合征为特征。胚胎期肾脏至少拥有3种谱系特异性祖细胞,通常祖细胞在人类出生前已消失,但在WT中依然存在,并有病理学研究发现胚胎残余肾组织(即肾源性剩余),因此普遍认为WT是一种胚胎性肿瘤,可以重现肾脏的组织学生长模式。肿瘤干细胞作为一种具有高度分化潜能的肿瘤细胞,亦被认为与WT的发生发展密切相关。WT的主要治疗方法是手术联合化疗,早期WT患儿5年生存率大于90%,但仍有部分患者死于肿瘤转移和复发。了解发育中肾脏的形成与调节,探索WT的胚胎干细胞起源,将有利于根据疾病发生发展采取相应治疗策略和判断疾病预后。
- Abstract:
- Characterized by multiple congenital anomalies,nephroblastoma (Wilms tumor,WT) is the most common renal malignancy in children.Embryonic kidney has at least three lineage-specific progenitor cells.Usually lost before birth,these cells with nephrogenic residue persist in WT.Therefore WT is an embryonic tumor reproducing the histological growth pattern of kidney.As one kind of tumor cells with high differentiation potential,tumor stem cells are also closely correlated with the occurrence and development of WT.Thanks to mainstay surgery plus chemotherapy,5-year survival rate of early stage WT has surpassed 90%.However,some patients still die from tumor metastasis and recurrence.Therefore a thorough understanding the formation and regulation of developing kidney and in-depth exploring the origin of embryonic precursors of WT may provide novel therapeutic strategies for managing WT.
参考文献/References:
[1] Nakata K,Colombet M,Stiller CA,et al.Incidence of childhood renal tumours:an international population-based study[J].Int J Cancer,2020,147(12):3313-3327.DOI:10.1002/ijc.33147.
[2] 洪博,董瑞.肾母细胞瘤治疗研究进展[J].临床小儿外科杂志,2021,20(6):569-575.DOI:10.12260/lcxewkzz.2021.06.012. Hong B,Dong R.Recent advances in the treatment of Wilms tumor[J].DOI:10.12260/lcxewkzz.2021.06.012.
[3] Mullen EA,Chi YY,Hibbitts E,et al.Impact of surveillance imaging modality on survival after recurrence in patients with favorable-histology Wilms tumor:a report from the Children’s Oncology Group[J].J Clin Oncol,2018,36(34):JCO1800076.DOI:10.1200/JCO.18.00076.
[4] Coorens THH,Treger TD,Al-Saadi R,et al.Embryonal precursors of Wilms tumor[J].Science,2019,366(6470):1247-1251.DOI:10.1126/science.aax1323.
[5] Islam M,Nishinakamura R.How to rebuild the kidney:recent advances in kidney organoids[J].J Biochem,2019,166(1):7-12.DOI:10.1093/jb/mvz021.
[6] Beckwith JB,Kiviat NB,Bonadio JF.Nephrogenic rests,nephroblastomatosis,and the pathogenesis of Wilms’ tumor[J].Pediatr Pathol,1990,10(1/2):1-36.DOI:10.3109/15513819009067094.
[7] Petrosyan A,Villani V,Aguiari P,et al.Identification and characterization of the Wilms tumor cancer stem cell[J].Adv Sci (Weinh),2023,10(20):e2206787.DOI:10.1002/advs.202206787.
[8] Rivera MN,Haber DA.Wilms’ tumour:connecting tumorigenesis and organ development in the kidney[J].Nat Rev Cancer,2005,5(9):699-712.DOI:10.1038/nrc1696.
[9] Fukuzawa R,Reeve AE.Molecular pathology and epidemiology of nephrogenic rests and Wilms tumors[J].J Pediatr Hematol Oncol,2007,29(9):589-594.DOI:10.1097/01.mph.0000212981.67114.ec.
[10] Young MD,Mitchell TJ,Vieira Braga FA,et al.Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors[J].Science,2018,361(6402):594-599.DOI:10.1126/science.aat1699.
[11] Lonergan GJ,Martínez-León MI,Agrons GA,et al.Nephrogenic rests,nephroblastomatosis,and associated lesions of the kidney[J].Radiographics,1998,18(4):947-968.DOI:10.1148/radiographics.18.4.9672980.
[12] Vujani? GM,Apps JR,Moroz V,et al.Nephrogenic rests in Wilms tumors treated with preoperative chemotherapy:The UK SIOP Wilms Tumor 2001 Trial experience[J].Pediatr Blood Cancer,2017,64(11):26547.DOI:10.1002/pbc.26547.
[13] Sandberg JK,Chi YY,Smith EA,et al.Imaging characteristics of nephrogenic rests versus small Wilms tumors:a report from the Children’s Oncology Group study AREN03B2[J].AJR Am J Roentgenol,2020,214(5):987-994.DOI:10.2214/AJR.19.22301.
[14] Dzhuma K,Ducou Le Pointe H,Coulomb A,et al.Wilms tumors and their precursors:radiological diagnosis versus histology[J].Pediatr Blood Cancer,2020,67(9):e28414.DOI:10.1002/pbc.28414.
[15] Short KM,Smyth IM.Branching morphogenesis as a driver of renal development[J].Anat Rec (Hoboken),2020,303(10):2578-2587.DOI:10.1002/ar.24486.
[16] Stupar Z,Chi S,Veszpremi B,et al.Wilms’tumour may also develop from impaired differentiation of the ureteric bud[J].Histopathology,2007,51(2):265-268.DOI:10.1111/j.1365-2559.2007.02741.x.
[17] Sarkany B,Kovacs G,Banyai D.Ureteric bud-derivatives in Wilms tumor and nephrogenic rest[J].In Vivo,2021,35(4):2159-2162.DOI:10.21873/invivo.12486.
[18] Sarkany B,Kuthi L,Kovacs G.Novel concept of Wilms’ tumor development:involvement of pluripotential cells of ureteric bud[J].Hum Pathol,2023,138:34-40.DOI:10.1016/j.humpath.2023.05.004.
[19] Fukuzawa R,Anaka MR,Morison IM,et al.The developmental programme for genesis of the entire kidney is recapitulated in Wilms tumour[J].PLoS One,2017,12(10):e0186333.DOI:10.1371/journal.pone.0186333.
[20] Sarlos DP,Yusenko MV,Peterfi L,et al.Dual role of KRT17:development of papillary renal cell tumor and progression of conventional renal cell carcinoma[J].J Cancer,2019,10(21):5124-5129.DOI:10.7150/jca.32579.
[21] Ihermann-Hella A,Lume M,Miinalainen IJ,et al.Mitogen-activated protein kinase (MAPK) pathway regulates branching by remodeling epithelial cell adhesion[J].PLoS Genet,2014,10(3):e1004193.DOI:10.1371/journal.pgen.1004193.
[22] Tee JB,Choi Y,Shah MM,et al.Protein kinase A regulates GDNF/RET-dependent but not GDNF/Ret-independent ureteric bud outgrowth from the Wolffian duct[J].Dev Biol,2010,347(2):337-347.DOI:10.1016/j.ydbio.2010.08.029.
[23] Packard A,Georgas K,Michos O,et al.Luminal mitosis drives epithelial cell dispersal within the branching ureteric bud[J].Dev Cell,2013,27(3):319-330.DOI:10.1016/j.devcel.2013.09.001.
[24] Kobayashi A,Mugford JW,Krautzberger AM,et al.Identification of a multipotent self-renewing stromal progenitor population during mammalian kidney organogenesis[J].Stem Cell Reports,2014,3(4):650-662.DOI:10.1016/j.stemcr.2014.08.008.
[25] Shukrun R,Pode-Shakked N,Pleniceanu O,et al.Wilms’ tumor blastemal stem cells dedifferentiate to propagate the tumor bulk[J].Stem Cell Reports,2014,3(1):24-33.DOI:10.1016/j.stemcr.2014.05.013.
[26] Huang L,Mokkapati S,Hu QH,et al.Nephron progenitor but not stromal progenitor cells give rise to Wilms tumors in mouse models with β-catenin activation or Wt1 ablation and Igf2 upregulation[J].Neoplasia,2016,18(2):71-81.DOI:10.1016/j.neo.2015.12.001.
[27] Wang YP,Zhou CJ,Liu YH.Wnt signaling in kidney development and disease[J].Prog Mol Biol Transl Sci,2018,153:181-207.DOI:10.1016/bs.pmbts.2017.11.019.
[28] Maiti S,Alam R,Amos CI,et al.Frequent association of beta-catenin and WT1 mutations in Wilms tumors[J].Cancer Res,2000,60(22):6288-6292.
[29] Drake KA,Chaney CP,Das A,et al.Stromal β-catenin activation impacts nephron progenitor differentiation in the developing kidney and may contribute to Wilms tumor[J].Development,2020,147(21):dev189597.DOI:10.1242/dev.189597.
[30] Weiss AC,Rivera-Reyes R,Englert C,et al.Expansion of the renal capsular stroma,ureteric bud branching defects and cryptorchidism in mice with Wilms tumor 1 gene deletion in the stromal compartment of the developing kidney[J].J Pathol,2020,252(3):290-303.DOI:10.1002/path.5518.
[31] Langner E,Cheng T,Kefaloyianni E,et al.Cep120 is essential for kidney stromal progenitor cell growth and differentiation[J].EMBO Rep,2024,25(1):428-454.DOI:10.1038/s44319-023-00019-z.
[32] Self M,Lagutin OV,Bowling B,et al.Six2 is required for suppression of nephrogenesis and progenitor renewal in the developing kidney[J].EMBO J,2006,25(21):5214-5228.DOI:10.1038/sj.emboj.7601381.
[33] Ozdemir DD,Hohenstein P.Wt1 in the kidney-a tale in mouse models[J].Pediatr Nephrol,2014,29(4):687-693.DOI:10.1007/s00467-013-2673-7.
[34] Hohenstein P,Pritchard-Jones K,Charlton J.The yin and yang of kidney development and Wilms’ tumors[J].Genes Dev,2015,29(5):467-482.DOI:10.1101/gad.256396.114.
[35] Gadd S,Huff V,Skol AD,et al.Genetic changes associated with relapse in favorable histology Wilms tumor:a Children’s Oncology Group AREN03B2 study[J].Cell Rep Med,2022,3(6):100644.DOI:10.1016/j.xcrm.2022.100644.
[36] Liu YM,Gao XX,Wang S,et al.Cancer stem cells are regulated by STAT3 signalling in Wilms tumour[J].J Cancer,2018,9(8):1486-1499.DOI:10.7150/jca.23277.
[37] Shi QL,Wu H,Li YL,et al.Inhibition of Wilms’ tumor proliferation and invasion by blocking TGF-β receptor I in the TGF-β/Smad signaling pathway[J].Biomed Res Int,2020,2020:8039840.DOI:10.1155/2020/8039840.
相似文献/References:
[1]何军,肖海波,王淑华,等. p53免疫组化判定肾母细胞瘤预后的研究[J].临床小儿外科杂志,2016,15(02):163.
[2]何炜婧,柳龚堡,董岿然..肾母细胞瘤伴静脉瘤栓的治疗探讨[J].临床小儿外科杂志,2017,16(05):426.
[3]王金湖,蔡嘉斌,李民驹,等.儿童肾母细胞瘤国际及国内诊治方案解读[J].临床小儿外科杂志,2020,19(09):765.[doi:10.3969/j.issn.1671-6353.2020.09.002]
Wang Jinhu,Cai Jiabin,Li Minju,et al.Recent international and domestic advances in the diagnosis and treatment of Wilms tumor[J].Journal of Clinical Pediatric Surgery,2020,19(07):765.[doi:10.3969/j.issn.1671-6353.2020.09.002]
[4]谢晨捷,顾松,田瑞成,等.儿童复发肾母细胞瘤的治疗及预后相关因素分析[J].临床小儿外科杂志,2021,20(05):430.[doi:10.12260/lcxewkzz.2021.05.007]
Xie Chenjie,Gu Song,Tian Ruicheng,et al.Treatment and prognostic factors of recurrent wilm’s tumor in children[J].Journal of Clinical Pediatric Surgery,2021,20(07):430.[doi:10.12260/lcxewkzz.2021.05.007]
[5]周恩卿,董瑞.黄连素在儿童胚胎源性肿瘤中的研究进展[J].临床小儿外科杂志,2023,22(12):1135.[doi:10.3760/cma.j.cn101785-202208042-008]
Zhou Enqing,Dong Rui.Research advances of berberine in pediatric embryonal tumors[J].Journal of Clinical Pediatric Surgery,2023,22(07):1135.[doi:10.3760/cma.j.cn101785-202208042-008]
[6]常晓峰,王焕民,王佳荣,等.细胞减灭术联合腹腔热灌注化疗在局部反复复发肾母细胞瘤治疗中的应用[J].临床小儿外科杂志,2024,(05):464.[doi:10.3760/cma.j.cn101785-202203047-012]
Chang Xiaofeng,Wang Huanmin,Wang Jiarong,et al.Application of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for locally recurrent Wilms tumor[J].Journal of Clinical Pediatric Surgery,2024,(07):464.[doi:10.3760/cma.j.cn101785-202203047-012]
备注/Memo
收稿日期:2022-7-24。
基金项目:唐仲英基金会项目(ZSBK0070)
通讯作者:董岿然,Email:kuiran@fudan.edu.cn